iCo Therapeutics and JDRF Team Up

iCo Therapeutics and JDRF Team Up

to Support Phase II Clinical Trial iDEAL for Diabetic Macular Edema 

--Trial that aims to address the leading cause of blindness

in people with type 1 diabetes and type 2 diabetes being led by Johns Hopkins investigators--

iDEAL Phase II Study Update

March 28, 2012, Vancouver, Canada—iCo Therapeutics (TSX-V: ICO), a Vancouver-based drug reprofiling company and JDRF, the largest charitable funder of type 1 Diabetes (T1D) research have joined forces to investigate a potential new treatment for one of the most common complications of diabetes, diabetic macular edema (DME).  The iDEAL study is a Phase II clinical trial to evaluate whether the drug iCo-007 could help to treat DME in people with either T1D or type 2 diabetes.  The study is being conducted at the Wilmer Eye Institute of the Johns Hopkins University School of Medicine.  

bit.ly/HnGkde via jdrf